Table 3.
Adverse events of patients receiving SRS plus ipilimumab (n = 46).
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |||||
|---|---|---|---|---|---|---|---|---|
| SRS before/ after Ipi |
SRS during Ipi |
SRS before/ after Ipi |
SRS during Ipi |
SRS before/ after Ipi |
SRS during Ipi |
SRS before/ after Ipi |
SRS during Ipi |
|
| Diarrhea/ nausea | 11 (35%) | 8 (53%) | 3 (10%) | 4 (27%) | 0 | 0 | 0 | 0 |
| Pruritus/ rash | 13 (42%) | 6 (40%) | 5 (16%) | 4 (27%) | 0 | 1 (7%) | 0 | 0 |
| Cardiopulmonary | 6 (19%) | 1 (7%) | 0 | 2 (13%) | 0 | 0 | 0 | 1 (7%) |
| Hepatitis | 0 | 0 | 1 (3%) | 0 | 2 (6%) | 1 (7%) | 0 | 0 |
| Fatigue | 16 (52%) | 8 (53%) | 3 (10%) | 3 (20%) | 0 | 0 | 0 | 0 |
| Headache | 1 (3%) | 3 (20%) | 1 (3%) | 1 (7%) | 0 | 0 | 0 | 0 |
| CNS bleeding (from treated BM) | 2 (6%) | 1 (7%) | 1 (3%) | 3 (20%) | 2 (6%) | 2 (13%) | 1 (3%) | 0 |
| Seizure | 0 | 0 | 2 (6%) | 1 (7%) | 0 | 2 (13%) | 0 | 0 |
| Cognitive change | 2 (6%) | 2 (13%) | 0 | 1 (7%) | 0 | 0 | 0 | 0 |
| Neurologic dysfunction | 2 (6%) | 2 (13%) | 0 | 0 | 0 | 0 | 0 | 0 |
SRS = stereotactic radiosurgery. Ipi = ipilimumab. CNS = central nervous system. BM = brain metastasis.